Rapid Micro Biosystems has announced a follow-on multi-system order from Samsung Biologics to expand deployment of its Growth Direct platform across the contractor’s manufacturing operations.
“Samsung Biologics is a leading global contract development and manufacturing organisation and we’re pleased to strengthen our partnership with this new multi-system order,” said Robert Spignesi, President and CEO of Rapid Micro Biosystems.
The Growth Direct system is designed to automate and modernise traditionally manual microbiology workflows, bringing quality control testing closer to the manufacturing environment.
The system is often used in the largest and most complex pharmaceutical manufacturing operations across the globe.
The order builds on an existing partnership between the two companies and supports the continued rollout of automated microbial quality control across Samsung Biologics’ global network.
According to the company, the platform delivers faster time to results, improved accuracy, and enhanced data integrity, supporting more efficient and compliant production processes.
Rapid Micro Biosystems said the latest order strengthens the collaboration between the two organisations and reflects continued adoption of automated MQC solutions within large-scale biopharmaceutical manufacturing.
The announcement follows a series of recent commercial milestones for the company, including multiple large system orders and continued growth in its installed base of Growth Direct systems.